Andere talen MoonLake Immunotherapeutics

Aandelen

MLTX

KY61559X1045

Geschatte realtime Cboe BZX Andere beurzen 20:36:39 04-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
41,97 ^USD	-0,05%		+0,62%	-30,52%

07/05	MoonLake Immunotherapeutics Q1 nettoverlies neemt toe	MT
07/05	MoonLake Immunotherapeutics rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa	16/05
MoonLake Immunotherapeutics Q1 Net Loss Widens	07/05
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update	07/05
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	10/04
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions	10/04
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions	10/04
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	11/03
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	10/03
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis	10/03
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	10/03
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024	04/03
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024	04/03
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,803,044, According to a Recent SEC Filing	01/03
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,540,710, According to a Recent SEC Filing	01/03
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss	29/02
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10	29/02
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab in Hidradenitis Suppurativa	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MoonLake Immunotherapeutics

Aandelen

MLTX

KY61559X1045

Andere talen

Filters